Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin.
The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -1.47 Increased by +81.51% | -1.69 Increased by +13.02% |
| May 15, 24 | -2.28 Decreased by -250.77% | -1.62 Decreased by -40.74% |
| Mar 26, 24 | -65.90 Decreased by -1.06 K% | -24.34 Decreased by -170.75% |
| Nov 9, 23 | -2.69 Increased by +67.98% | -2.06 Decreased by -30.58% |
| Aug 10, 23 | -7.95 Increased by +86.84% | -4.70 Decreased by -69.15% |
| May 4, 23 | -0.65 Increased by +93.98% | -0.54 Decreased by -20.37% |
| Mar 16, 23 | -5.68 Increased by +45.38% | -3.70 Decreased by -53.51% |
| Nov 10, 22 | -8.40 Decreased by -31.25% | -8.80 Increased by +4.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.14 M Decreased by -22.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -7.12 M Decreased by -1.07 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Increased by +100.00% | -6.47 M Decreased by -36.78% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Increased by +100.00% | -7.83 M Decreased by -77.90% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Increased by +100.00% | -5.83 M Increased by +73.64% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -608.00 K Increased by +83.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | -1.64 M Decreased by -34.81% | -4.73 M Decreased by -33.74% | Increased by +288.95% Decreased by -0.80% |
| Sep 30, 22 | -1.59 M Decreased by N/A% | -4.40 M Decreased by -105.51% | Increased by +277.03% Decreased by N/A% |